Novavax

Coordinates: 39°08′14″N 77°13′33″W / 39.1371167°N 77.2258056°W / 39.1371167; -77.2258056

Novavax, Inc. is a clinical-stage vaccine company headquartered in Gaithersburg, Maryland with additional facilities in Rockville, Maryland and Uppsala, Sweden. Novavax is a public company that trades under the symbol "NVAX".

In June 2013, Novavax acquired the Matrix-MTM adjuvant platform with the purchase of Swedish company Isconova AB and renamed it Novavax AB.

In 2015 the company received an $89 million grant from the Bill & Melinda Gates Foundation to support the development of a vaccine against human respiratory syncytial virus for infants via maternal immunization.

In March 2015 the company completed a Phase I trial for its Ebola vaccine candidate.

In September 2016 the company announced that a Phase III trial of its RSV vaccine had failed to meet its endpoints, which caused its share price to fall from $8.34 to $1.40 and led the company to lay off 30% of its employees.

As of November 2016 its RSV F vaccine candidate was in three clinical trials.

This page was last edited on 6 September 2017, at 23:10.
Reference: https://en.wikipedia.org/wiki/Novavax under CC BY-SA license.

Related Topics

Recently Viewed